Solara confirms no deviation in ₹309.8 crore rights issue proceeds for Q4 FY2026; Audit Committee approved the update to exchanges; funds utilized per original objects with repayments of borrowings.
AI Assistant
Solara Active Pharma Sciences Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.